Search

This study takes stock of business and economics research on Artificial Intelligence (AI) and provides a dynamic panorama of the overall knowledge structure of this ever-growing body of work ever since its inception in 1966. Our bibliometric analysis based on the full archive of 1024 studies identifies the main trends of and the major intellectual contributors to the extant knowledge of AI in business and economics research. Specifically, our results show that (1) AI-focused business and economics research wintnessed growth over three stages, particularly with a sharp increase after 2017. (2) While this body of research has gained tremendous momentum across the globe, the United States is by far the center of knowledge generation. (3) Research collaborations are still limited in this area. (4) Research topics flourished, ranging from early decision support systems, neural networks, and scheduling methods to more recent machine learning, automation, and big data. This study also identifies fruitful avenues for further business and economics research with an AI focus. [ABSTRACT FROM AUTHOR]

Objectives: The patent linkage system upgraded patent challenges to an important factor in granting timely market approval for generic drugs. We aim to understand patent challenges and identify the factors that are associated with successful patent challengers under the patent linkage system in South Korea.Methods: We constructed a novel dataset that combined information on manufacturers with detailed data about their patent challenges after introduction of the patent linkage system. Based on the number of successful patent challenges, manufacturers were categorized into non-challengers, passive challengers, and aggressive challengers. Then, two types of logistic models were applied to identify the factors associated with successful and aggressive challengers.Findings: Only 39 active ingredients were challenged by 77 manufacturers from March 2015 to December 2019. Of 171 manufacturers, 94 (55 %) were non-challengers, 58 (34 %) were passive challengers who had succeeded in fewer than 4 patent challenges, and 19 (11 %) were aggressive challengers who had succeeded in 4 or more patent challenges. Higher sales, more employees, and a greater number of reimbursed drugs were associated with being a patent challenger, while a greater number of reimbursed drugs was associated with being an aggressive challenger.Conclusion: Some manufacturers utilize patent challenges to strengthen their product portfolios in the market. However, under the patent linkage system, the frequency of patent challenges is limited in South Korea compared to the United States. In particular, patent challenges against drugs in injection form and biologics are very rare. [ABSTRACT FROM AUTHOR]